ArticleBlood cancer journal2022
Novel CD19 chimeric antigen receptor T cells manufactured next-day for acute lymphoblastic leukemia.
Article in Blood cancer journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- BCMA-BBZ-OX40 CAR-T Therapy Using an Instant Manufacturing Platform in Multiple Myeloma.Journal for immunotherapy of cancer · 2024Trial
- Transduction efficiency in clinical CAR T cell products: A retrospective study at a single center.Molecular therapy. Advances · 2026Article
- Recipient-derived vs. donor-derived CAR-T-cell therapy in relapsed B-cell acute lymphoblastic leukemia patients after transplantation: A multi-center retrospective study.Chinese medical journal · 2026Observational
- Development of a 3-day manufacturing method to generate CD19-CD20-CD22 trispecific CAR T-cells from whole blood.Journal of translational medicine · 2026Article
- BCMA/CD19 dual-targeting CAR T-cell therapy in older patients with newly diagnosed multiple myeloma: a phase 1 study.Blood advances · 2026Article
- Microgravity-cultured glioblastoma organoids integrated with microfluidic chip for CAR-γδ T evaluation.Communications biology · 2025Article
- Optimizing CAR T cell therapy for solid tumours: a clinical perspective.Nature reviews. Clinical oncology · 2025Review
- Asparaginase enhances CAR-T cell antitumor immunity by asparagine metabolic reprogramming and central memory induction in ALL.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- New power in cancer immunotherapy: the rise of chimeric antigen receptor macrophage (CAR-M).Journal of translational medicine · 2025Review
- Recent advances in CAR-MSCs: the new engine of cellular immunotherapy evolution.Journal of hematology & oncology · 2025Review
- Article
- Presetting CAR-T cells during ex vivo biomanufacturing.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Review
- New insights on potency assays from recent advances and discoveries in CAR T-cell therapy.Frontiers in immunology · 2025Review
- Development and application of machine learning models for hematological disease diagnosis using routine laboratory parameters: a user-friendly diagnostic platform.Frontiers in medicine · 2025Article
- "Dissecting the role of T cell exhaustion in cancer progression: a multifaceted approach".Frontiers in immunology · 2025Review
- Afatinib boosts CAR-T cell antitumor therapeutic efficacy via metabolism and fate reprogramming.Journal for immunotherapy of cancer · 2024Article
- Long-term survival with donor CD19 CAR-T cell treatment for relapsed patients after allogeneic hematopietic stem cell transplantation.Journal of hematology & oncology · 2024Article
- In vivo manufacture and manipulation of CAR-T cells for better druggability.Cancer metastasis reviews · 2024Review
- Early induction of cytokine release syndrome by rapidly generated CAR T cells in preclinical models.EMBO molecular medicine · 2024Article
- Current advances in experimental and computational approaches to enhance CAR T cell manufacturing protocols and improve clinical efficacy.Frontiers in molecular medicine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chimeric antigen receptor-engineered T (CAR-T) cells have shown promising efficacy in patients with relapsed/refractory B cell acute lymphoblastic leukemia (R/R B-ALL). However, challenges remain including long manufacturing processes that need to be overcome. We presented the CD19-targeting CAR-T cell product GC007F manufactured next-day (FasTCAR-T cells) and administered to patients with R/R B-ALL. A total of 21 patients over 14 years of age with CD19
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.